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Background: In 01/2011 Clalit Health Services (CHS), changed the LDL-Cholesterol target definitions in its quality
indicators program, from a universal target to values stratified by risk assessment based on ATP III criteria. The
objective of this study is to evaluate the effect of this change on achievement of LDL-C targets and on physicians’
prescriptions of statins.
Study Design: A descriptive study based on administrative dataset 06/2010-06/2012.
Methods: Setting: CHS, The largest health maintenance organization in Israel that insures above 4,000,000
beneficiaries.
Patients: Patients who had been in the same risk group throughout the study period.
Measurements: Attainment of targets for LDL-C and purchases of statins prior to, and following, implementation of
the guidelines in the CHS quality indicators program.
Results: 433,662 patients remained in the same risk groups throughout the study period; 55.8% were women; the
average age was 53.0 ± 10.3 years; 63.9%, 13.4%, and 22.7% were at low, medium, and high risk respectively. After
implementation, the proportion of patients reaching LDL-C targets increased in all risk groups: from 58.6% to 61.6%,
from 55.1% to 61.1%, and from 44.5% to 49.0%, in low, medium, and high risk groups respectively (p < 0.001). The
proportion of patients treated with potent statins increased in all risk groups; from 3.4% to 5.6%, from 6.7% to
10.3%, and from 14.5% to 20.3% respectively (p < 0.001).
Conclusion: The risk stratification approach as a basis for the quality indicators program was implemented and
better achievement of target LDL-C levels ensued. We suggest that implementation of quality indicators that are
consistent with the current literature can lead to improvements that exceeds temporal trends.
Keywords: Quality indicators, Clinical guidelines, Hypercholesterolemia, StatinsBackground
Healthcare services operate in increasingly complex
environments, characterized by growing specialization,
fragmentation of medical care, and soaring costs that do
not always reflect healthcare value. Healthcare quality
assurance programs aim to enhance the extent to which
healthcare services achieve desired outcomes, according
to the prevailing professional literature. An increasing
number of pay-for-performance systems employ financial
incentives to achieve quality measures that are focused on* Correspondence: arcohen@clalit.org.il
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unless otherwise stated.health outcomes, rather than on process-of-care [1]. How-
ever, the pay-for-performance model has been reported to
yield only modest [2] and even negligible and inconsistent
improvements in healthcare quality [3,4], and the costs of
such programs have yet to be assessed [5].
The National Cholesterol Education Program Adult
Treatment Panel III (ATP III) guidelines serves as the
benchmark for the assessment of the quality of treatment
of hyperlipidemia [6]. Published studies have demon-
strated low adherence to them, despite assessment of their
relative cost-effectiveness [7]. For example, Barham et al.
found that the challenge facing implementation of ATP III
guidelines is much greater for intermediate- and high-risk
patients than for low-risk patients. [8]. Lee et al. also noted
that the rate of achieving target LDL-C levels was lower inThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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Computerized clinical decision support systems, including
recommendations tailored to patient characteristics, have
been shown to mildly increase physician adherence to
ATP III guidelines [10], but not to exert a statistically sig-
nificant effect on LDL-C target achievement [11]. Nume-
rous barriers to guideline adherence by physicians have
been identified [12].
All Clalit Health Services (CHS) institutions are re-
quired to measure and follow their performance in core
clinical areas of operation including both processes of
care and healthcare outcomes. At the beginning of every
calendar year, CHS publishes its quality indicator pro-
gram for the upcoming year, with details of targeted
changes and the rationale behind them. Guidelines and
performance updates are transferred electronically to all
CHS physicians and nurses on a monthly basis.
In 2006, CHS set an ambitious target of LDL choles-
terol < 100 mg/dl, to be reached by 90% of patients who
are after therapeutic cardiac catheterization or coronary
artery bypass grafts, 65% of patients with diabetes, and
20% of the remaining individuals with hyperlipidemia. In
January 2011, the CHS program of quality indicators
was revised and the ATP III guidelines for the manage-
ment of dyslipidemia of patients without diabetes or ac-
tive ischemic heart disease were used as a guide for risk
stratification [6]. Accordingly, all members of CHS with-
out diabetes or ischemic heart disease were stratified by
risk assessment and the automatic reminders for CHS
physicians were changed accordingly.
The aim of the current study was to evaluate the
longitudinal effect of these changes on achievement of
LDL-C targets, and on the delivery of care, as measured
by medication purchases.
Methods
This is a descriptive study based on an administrative
dataset of purchases of statins and of attainment of risk
stratified targets for LDL-C prior to, and following, im-
plementation of ATP III based guidelines in CHS quality
indicators program.
Data sources
Data were accessed from the CHS data warehouse. CHS
is the largest health maintenance organization in Israel,
insuring and providing healthcare to more than 50% of
Israel’s population (more than 4,000,000 beneficiaries).
Every person insured by CHS is under the care of a pri-
mary care physician (PCP), either a family physician or a
pediatrician. Patients only see the PCP to whom they are
assigned (except for when their physician is on vacation,
when they are out of town, or when there is urgency and
their physician is not available). For each visit to a diffe-
rent PCP, a special administrative certificate of approvalis needed and the peer physician is instructed to provide
only “first aid”. Hence, provision of primary care in CHS
is characterized by a high level of continuity [13].
The CHS information system is comprehensive, com-
prising socio-demographic data; information on the utili-
zation of healthcare services, drug purchases, laboratory
and imaging tests, and a wide-scale registry of chronic
diagnoses [14]. The epidemiology unit of the CHS main-
tains a central comprehensive chronic diseases registry.
This registry is continuously updated, based on an algo-
rithm integrating all available data (hospitalization dis-
charge diagnoses, chronic diagnoses in the PCP electronic
medical record, laboratory test results, drug purchases
and other sources). CHS’s registry of patients with chronic
diseases serves as the foundation for calculations of
healthcare quality indicators for several chronic conditions
such as hypertension, diabetes, and ischemic heart disease.
All community pharmacies operated by CHS are com-
puterized and report to a central data repository. All
prescriptions of statins that were filled by CHS members
between June 1, 2010 and June 31, 2012 were docu-
mented. CHS dispenses medications with nominal and
almost equal co-payment, which ensures that all pre-
scriptions are documented and that drug selection is not
influenced by financial considerations. The formulary
choices offered did not change over the study period, as
generic atorvastatin had been introduced on 07/2010
and generic rosuvastatin on 06/2010.
LDL-c tests were performed in the CHS central la-
boratories, using the same techniques during the study
period.
Patient population
The CHS chronic disease registry identifies people with
diabetes and after therapeutic cardiac catheterization or
coronary artery bypass grafts, for whom the LDL-C tar-
get is <100 mg %. These patients have different quality
indicator sets. For all other patients with a diagnosis of
hyperlipidemia in CHS registry, cardiovascular risk was
assessed based on the ATP III. The following variables
were used to assess risk: age and gender, smoking status
(patients for whom smoking status was missing were re-
corded as “non-smokers”), hypertension, cardiovascular
diseases (ischemic heart disease without therapeutic car-
diac catheterization or coronary artery bypass grafts,
peripheral vascular disease, state after cerebrovascular
accident), and most recent HDL level (on June 2010 and
again on June 2012). We did not have data on family
history of cardio-vascular diseases.
We stratified the risk groups according to a modifica-
tion to the ATP III:
 Patients with 0–1 risk factors were classified as
“low risk” with LDL-C target of <160 mg/dl.
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“moderate risk” with LDL-C target of <130 mg/dl.
 Patients with > =3 risk factors or with proven
cardiovascular diseases were classified as “high risk”
with LDL-C target of <100 mg/dl.
510,166 patients were included in the QI program in
06/2010, of them 76,504 changed risk group during the
study period and 433,622 were in the same risk group in
06/2012. Only patients who had been in the same risk
group throughout the study period (June 2010 to June
2012) were included in the analysis.
Demographic data included: Age, gender and socio-
economic status (SES); low SES was defined as exemp-
tion from social security payments.
Main outcome measures
1. The proportion of patients who reached the LDL-C
target value for their risk category.
2. The proportion of patients using potent statins
(Atorvastatin and Rosuvastatin) and first- line statins
(all other statins) in each risk category.
Outcomes were assessed every six months, starting six
months prior to implementation of the stratified ap-
proach, and continuing until 18 months after imple-
mentation. As it was a retrospective study we evaluated
at each point only patients with a valid LDL-C test
(a valid test had been defined as a test done in the last
12 months).
The study was approved by Clalit Health Services
ethics committee. The committee states that there is no
need of informed consent of study subjects.
Statistical analysis
Comparison between three groups of patients (low,
medium, and high risk) with regard to demographic
parameters (gender, age, etc.) was performed using one-
way analysis of variance (ANOVA) and Chi-square tests,
as applicable.
ANOVA with repeated measures (over time) was per-
formed to assess the time trend in the various outcome
parameters (prescription of statins, achievement of LDLTable 1 Sociodemographic characteristics of the study popula
Total Low risk
Number of individuals 433,662 277,234
% of the cohort 100% 63.9%
Age - mean (SD) 53.0 (10.3) 49.2 (12.7)
Males (%) 44.2% 34.2%
Low socioeconomic status (%) 34.9% 34.8%
aFor difference between the three groups.targets). Contrast analysis was used to compare succes-
sive time points vs. baseline.
The statistical significance level was set to 0.05 and the
SPSS for Windows software, version 19.0 (Chicago, IL),
was used for the analysis.
Results
The study population included all the 433,362 patients of
CHS who remained in the same risk group throughout
the study period. Their socio-demographic characteristics
are summarized in Table 1. Patients in the low risk ca-
tegory tended to be younger (p < 0.001), and a larger pro-
portion were females (p < 0.001). Patient risk factors are
summarized in Table 2.
Figure 1 depicts the trend of target LDL-C achievement
according to risk categories. At the beginning of the pro-
gram target LDL-C achievement was 46.0%, 55.1% and
58.7% in the high, medium and low risk groups respec-
tively. Small changes (and even a decline) were observed
in the first six months after launching the program.
Changes became more prominent and significant one year
after the introduction of the new stratified targets. At the
end of 18 months follow-up, target LDL-C achievement
was significantly higher: 49.0%, 61.1% and 61.6% in the
high, medium and low risk groups, respectively.
Figures 2 and 3 demonstrate the secular relationship
of first line and potent statin utilization, respectively. For
all risk categories there was a significant continual de-
cline in the use of first-line statins and a parallel increase
in the percent of individuals on potent statins. The pre-
scription of first- line statins declined from 31.0% to
26.0%, from 38.4% to 34.1%, and from 20.4% to 18.2% in
the high, medium and low risk groups respectively. The
prescription of potent statins increased from 16.4% to
20.3%, from 7.7% to 10.3%, and from 4.0% to 5.6% in the
high, medium and low risk groups respectively. The mag-
nitude of the change was greater for higher risk categories.
Changes in prescription habits, as reflected by statin pur-
chases, preceded changes in achieving LDL targets.
Discussion
This study showed that the rate of achievement of target
LDL-C decreased during the first 6 months after the im-
plementation of the stratified approach, yet increasedtion
Moderate risk High risk p valuea
58,214 98,214
13.4% 22.7%
60.4 (7.8) 59.2 (10.3) <0.001
52.3% 78.7% <0.001
32.3% 36.7% <0.001
Table 2 Risk factors of participants according to ATPIII
Total Low risk Moderate risk High risk
Number of individuals 433,662 277,234 58,214 98,214
Male (> = age 45 years) 140,965 (32.5%) 50,264 (18.1%) 29,185 (50.1%) 61,516 (62.6%)
Female (> = age 55 years) 127,264 (29.3%) 76,815 (27.7%) 26,721 (45.9%) 23,728 (24.2%)
Current smoking 76,621 42,933 8,710 24,978
Low HDL cholesterol 56,290 15,650 10,614 30,026
Hypertension 125,128 22,410 45,631 57,087
Ischemic heart disease 59,931 0 0 59,931
State after cerebrovascular accident 21,864 0 0 21,864
Peripheral vascular disease 10,436 0 0 10,436
High HDL cholesterola 80,789 69,236 1,181 10,372
aHigh HDL cholesterol – is a protective factor (in patients with high HDL cholesterol the score of risk factors is subtracted by one).
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statins decreased and purchases of potent statins in-
creased in a complementary manner, starting from six
months after implementation of stratified quality indica-
tors based on ATP III guidelines. This was true for indi-
viduals in all three cardiovascular risk categories, and
continued throughout the 18 month study period. This
temporal change in process of care and patient out-
comes may be partially explained by the influence of theP-values Overall 06/2010-
12/2010 
Low <0.001 0.039 
Medium <0.001 0.762 
High <0.001 <0.001 
Figure 1 The proportion of patients, stratified by cardiovascular risk who a
(program launched on January 1, 2011).healthcare policy change on physicians’ clinical behavior
[15]. Financial incentives were not awarded, nor imme-
diate health benefit conferred. Thus, physician recog-
nition of the value of quality measures and confidence in
their validity might be the prime factors determining
their improved adherence.
More than 10% of the total number of beneficiaries of
CHS comprised the population of the current study.






0.056 <0.001 <0.001 
<0.001 <0.001 <0.001 
0.547 <0.001 <0.001 









Low <0.001 0.001 0.004 <0.001 <0.001 
Medium <0.001 0.079 <0.001 <0.001 <0.001 
High <0.001 0.085 <0.001 <0.001 <0.001 
Figure 2 Monthly first line statin prescriptions (program launched on January 1, 2011).
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numbers of patients over the course of years, with rela-
tively high estimations of numbers needed to treat (NNT)
to prevent a medical event [16,17]. Since the patients eva-
luated in the current study had already been diagnosed
with hyperlipidemia based on earlier recommendations,
CHS guidelines recommended measuring their lipid levels
annually. Moreover, physicians received reminders when
opening a patient’s computerized file to repeat lipid profile
testing if more than a year had passed since previous
testing.
The earlier CHS policy of a uniform LDL-C target did
not result in improved control of hyperlipidemia, even
though identical effective, convenient, medical treat-
ments with minimal side effects were available. More-
over, the goal of reaching this target in 20% of the
hyperlipidemic population could even have an opposite
effect, with physicians preferring to focus on patients
who seemed easier to treat rather than those in most
need of treatment. We found differences in the use of
first-line statins, and particularly in the use of potent sta-
tins, among patients with different risk levels, even be-
fore implementation of the ATP III guideline- based
quality indicators. Such deviation from the uniform tar-
get established in CHS during that period attests todifferences in clinical decision making when targets were
not based on established clinical guidelines published in
the medical literature. Ongoing updating of quality indi-
cators and clinical targets according to current scientific
knowledge is thus especially important, as is assessment
of the benefits expected in physician behavior [18].
We observed a lag of six months in the improvement
in patients’ lipid profiles after the implementation of the
new quality indicators. Possible reasons for the time
lapse in perceived improvement were: the large popula-
tion involved, which in some cases comprised up to 15%
of a physician’s patients list, and the time required for a
physician to identify relevant patients, to evaluate their
willingness to a change in treatment, to enact the change,
and to conduct a follow-up blood test to verify its effect.
Even at the end of the study period, fewer than half
(46.3%) of the individuals classified with high cardio-
vascular risk purchased statins. Similarly, less than half
(49%) reached the LDL-C target. Non-interventional stu-
dies have shown comparable rates for both statin use and
LDL-C target achievement among high risk patients. Data
from the United States National Health and Nutritional
Examination Survey (NHANES) showed 54.4% of indi-
viduals with diabetes to achieve LDL-C < 100 mg/dL in









Low <0.001 <0.001 <0.001 <0.001 <0.001 
Medium <0.001 <0.001 <0.001 <0.001 <0.001 
High <0.001 <0.001 <0.001 <0.001 <0.001 
Figure 3 Monthly potent statin prescriptions (program launched on January 1, 2011).
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LDL-C, even though 96% were taking statins, yet physi-
cians perceived that 71% achieved the targets [20]. Other
Israeli studies found that achievement of LDL-C targets
among patients with hyperlipidemia with diabetes or
established cardio-vascular diseases is also sub-optimal
[21-24]. Achieving LDL-C levels of less than 100 mg/dl
were 65-67% among patients with coronary disease
[21,23,24], 57% in diabetic patients [23] and 46.7% among
patients with peripheral vascular disease [24].
Underutilization of lipid-lowering drugs among indi-
viduals with diabetes has also been reported in studies
conducted in Germany [25] and in China [26]. In a study
of individuals who were referred to a lipid clinic, LDL-C
targets were reached by only 20% and 45% of those not
treated and treated with statins, respectively [27].
18 months after change in quality indicators defi-
nitions 3%, 6% and 2.9% more of the hyperlipidemia
patients with high, medium and low risk respectively
achieved target LDL-C levels. It means additional 1,500,
1,800 and 2,900 patients at the high, medium and low
risk groups respectively. Published literature suggests
that the effect observed is clinically significant and has
the potential to result in a significant reduction in major
coronary events [28,29].A main strength of the current study is the two year
follow-up of all patients classified in the same risk cate-
gories in a large health maintenance organization. This
precludes the selection bias confronting prospective
studies that include only physicians and clinics who
express willingness to participate [10,11]. The current
study also contrasts with investigations that assessed tar-
get achievement as reduction in cholesterol, without
stratification by risk groups [30]. The comprehensive
and valid data warehouse of CHS, including drug pur-
chases and laboratory tests is another strength of the
study. Perhaps most important, we demonstrated a static
situation before the declared implementation of ATP III
guideline quality indicators, changes in statin use follo-
wing the policy change, and increased achievement of
LDL-C targets subsequent to the changes in statin use.
Still, the study design does not afford conclusions re-
garding causality; and neither individual patient changes
nor adherence of physicians to ATP III guidelines were
assessed. Nevertheless, the temporal change observed,
first in increased purchases of potent statins, and then in
increased rate of LDL-C target achievement, suggests a
relationship between these outcomes.
This study has a number of additional limitations. We
stratified the patients to three risk groups according to
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family history of ischemic heart disease or to follow the
risk classification calculation on the entire hyperlipi-
demic population of the CHS so there may be some mis-
classification in our cohort. But misclassification would
be expected to be mainly in the direction of putting pa-
tients with high risk into a lower risk group, so the
thrust of the PCPs in the program would not be affected.
We cannot refute the possibility that factors other than
those investigated may have affected clinical decision
making and outcomes. No changes in approvals or co-
payments of relevant drugs occurred during the study
period in the face of the expiration of patents on Atorva-
statin and Rosuvastatin in Israel at the beginning of the
study period. However, it may be that approval policy of
potent statins had become more liberal even before the
study period, pending the introduction of generics.
We presume that changes in the National Quality
Indicators initiative at that period did not have any effect
on PCPs behavior in CHS, as treatment goals in the
CHS were more ambitious throughout the study period.
There were no results of large relevant studies or essen-
tially different clinical guidelines published that could be
expected to affect the behavior of the physicians or the
general population. The only developments were the
notification of physicians of the change in CHS quality
indicators regarding treatment of hyperlipidemia, and
updates in the reminders in the personal computerized
file of patients consistent with the policy change.
Conclusions
In conclusion, we found that a change in the definition of
the quality indicators for the treatment of hyperlipidemia
was associated with a change in physician behavior and
with improvement in the rate of achievement of target
values within 18 months of implementation. The findings
suggest that implementation of a quality measure that is
tied to established and accepted clinical guidelines, in a
setting where physician results are tracked, has the poten-
tial to motivate physician behavior and achieve improved
clinical results (beyond temporal trends), even in the ab-
sence of direct “pay for performance” incentives.
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